U.S. markets closed

Pharmadrug Inc. (PHRX.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.03000.0000 (0.00%)
At close: 01:50PM EDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0300
Bid0.0300 x N/A
Ask0.0350 x N/A
Day's Range0.0300 - 0.0350
52 Week Range0.0250 - 0.0650
Avg. Volume223,654
Market Cap10.6M
Beta (5Y Monthly)3.29
PE Ratio (TTM)N/A
EPS (TTM)-0.0170
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for PHRX.CN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Newsfile

      Pharmadrug Announces Closing of Sale of German Cannabis Assets

      Toronto, Ontario--(Newsfile Corp. - August 3, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("Pharmadrug" or the "Company"), is pleased to announce that it has closed the previously announced (see press release dated May 31, 2022) sale of all of the issued and outstanding securities of Pharmadrug Production GmbH ("Pharmadrug GmbH") to Khiron Life Sciences Corp. (TSXV: KHRN) ("Khiron"). Pharmadrug GmbH, is a German medical cannabis distributor, with a Schedule I European Union narcotics ...

    • Newsfile

      PharmaDrug Announces Non-Brokered Offering of $650,000 of Convertible Secured Debentures and Issuances of Common Shares

      Toronto, Ontario--(Newsfile Corp. - August 2, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and naturally-derived approved drugs, is pleased to announce that it has raised $650,000 through the sale of debenture units ("Units"). Each unit is comprised of a $1,000 principal amount convertible secured

    • GlobeNewswire

      Healthcare Breakthroughs: KZR, NMLSF, AGRX, LMLLF Report Latest Advances in Novel Therapeutics for Inflammatory Diseases, Oncology, and Autism

      NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Kezar Life Sciences (NASDAQ: KZR), Nova Mentis Life Sciences (OTC: NMLSF), Agile Therapeutics (NASDAQ: AGRX), and PharmaDrug (OTC: LMLLF) (CSE: PHRX). As the global pharma market surpasses $1.3 trillion dollars (Statista), emerging technologies and healthcare research innovations are unleashing new exponential gr